Characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCharacterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Drug Alias Name自体软骨细胞体外表达蛋白ChondroCelect-3DChondroCelectTGX-002FAB-002 +[6] 
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Cartilage cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionCartilage replacements
TargetsNot applicable
Therapy Area/IndicationsCartilage Diseases
Global Approved IndicationsCartilage Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/10/05
Country/TerritoryBelgiumNetherlandsGermany +[5] 
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesTigenix Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTigenix Nv
Active IndicationsN/A
Inactive IndicationsCartilage Diseases

Other Information

ATC CodeM09AX02
Related LinksN/A